Aprea Therapeutics, the Doylestown, Pennsylvania-based precision oncology company, announced on August 28, 2026 an expansion of its intellectual property portfolio covering its two lead drug programs, bringing its total holdings to 28 issued patents and 30 pending applications worldwide. President and CEO Oren Gilad, Ph.D., tied the expanded portfolio directly to the company’s competitive positioning: “Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine. A strong global intellectual property portfolio is a critical component of our strategy, supporting the advancement of potentially best in class oncology therapies while protecting the long-term value of our programs. We remain focused on strengthening our intellectual property position as we advance our pipeline and pursue new treatment options for patients with difficult-to-treat cancers.”
Two Programs, Two Very Different Patent Runways
The company’s WEE1 kinase inhibitor program, anchored by lead candidate APR-1051 and currently in the Phase 1 ACESOT-1051 trial, covers two pending U.S. patent applications, one pending U.S. provisional application, two granted patents outside the U.S. in Australia and Korea, and 12 additional pending applications internationally. If granted, the pending applications could provide patent protection through 2047, before accounting for any additional regulatory exclusivity. The WEE1 portfolio covers key aspects of the program, including proprietary compounds, pharmaceutical compositions and methods of use. APR-1051 is being evaluated in advanced/metastatic solid tumors harboring certain cancer-associated gene alterations.
The company’s ATR inhibitor program, built around ATRN-119, has a more developed granted-patent estate: four granted U.S. patents, one pending U.S. application, one pending international application, 22 granted patents outside the U.S., and 13 additional pending applications. Its granted patents run through 2035 to 2037, while pending applications could extend protection to 2045, on top of up to five additional years of regulatory exclusivity that may be available separately. The portfolio covers proprietary compounds, pharmaceutical compositions and methods of use. In 2025, Aprea determined a recommended Phase 2 monotherapy dose of 1,100 mg once daily for ATRN-119 in the ABOYA-119 Phase 1/2a dose-escalation study, then closed the study to focus resources on APR-1051. The company is considering further development of ATRN-119 through combination approaches, including with radiation therapy, chemotherapy, antibody-drug conjugates and immune checkpoint inhibitors.
Both Lead Programs Trace Back to a Single 2022 Acquisition
APR-1051 and ATRN-119 both trace their origins to Aprea’s May 2022 acquisition of Atrin Pharmaceuticals, a stock-for-stock deal in which former Atrin shareholders received approximately 58.8% of the combined company’s shares on a pro forma basis. Atrin’s ATR inhibitor, then called ATRN-119, and its WEE1 inhibitor, then called ATRN-1051, became the foundation of Aprea’s current pipeline. The transaction also provided Aprea’s pre-merger shareholders with contingent value rights tied to potential proceeds from certain of Aprea’s legacy p53-targeted assets.
About Aprea Therapeutics
Aprea Therapeutics is a clinical-stage precision medicine oncology company focused on developing targeted therapies for patients with biomarker-defined cancers. Its approach centers on synthetic lethality, a strategy intended to exploit specific vulnerabilities in cancer cells while potentially limiting effects on normal cells. The company’s two lead programs are APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, an oral small-molecule inhibitor of ATR, both being developed for solid tumor indications. Aprea is currently prioritizing the clinical development of APR-1051, while evaluating potential combination approaches for ATRN-119.
